Evaluating the effects of empagliflozin in preventing myocardial damage in patients undergoing percutaneous coronary interventio

Phase 3

Recruiting

• Conditions: Cardiovascular disease.; Cardiovascular disease, unspecified; 429.2

• Registration Number: IRCT20221102056378N1
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Age 18-80 years
Ischemic heart diseases patients
candidate for angioplasty and stentstent insertion
Filling of consent form

Exclusion Criteria

History of infarction
History of open heart surgery in the last 3 months
Renal dysfunction
Dialysis
Failed History of Coronary Angioplasty
cardiogenic shock
cancer
Liver failure
Autoimmune disease
Pregnancy
History of serious allergy to empagliflozin
Inability in filling and understanding of the consent form

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CTnI level. Timepoint: 8 hours and 24 hours after the intervention. Method of measurement: ELISA kits.;Hs-CRP level. Timepoint: 24 hours after the intervention. Method of measurement: ELISA kits.

Secondary Outcome Measures

Name	Time	Method
Major Adverse Cardiac Effects. Timepoint: 1 month after hospital discharge. Method of measurement: Follow up by phone.